Mitochondrial and peroxisomal dysfunction following perinatal exposure to antiretroviral drugs.
Stojanov
S
S
Wintergerst
U
U
Belohradsky
B H
BH
Rolinski
B
B
D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D019259:Lamivudine / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008928:Mitochondria / Q000187:drug effects* / Q000502:physiology; D018743:Perinatal Care; D020675:Peroxisomes / Q000187:drug effects* / Q000502:physiology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D011297:Prenatal Exposure Delayed Effects; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D019258:Saquinavir / Q000627:therapeutic use; D015215:Zidovudine / Q000009:adverse effects* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D019258:Saquinavir; D019438:Ritonavir